Cullinan Therapeutics, Inc.
CGEMNASDAQHealthcare● Active
$13.53
+$0.25(+1.84%)
Market Cap$831219427
P/E Ratio—
52W High$16.74
52W Low$5.68
Cullinan Therapeutics, Inc. (CGEM) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CGEM · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.22B) | ($0.17B) | ($0.15B) | $0.11B | ($0.07B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.04B | $0.04B | $0.03B | $0.03B | $0.02B |
| Change in Working Capital | $0.01B | ($0.00B) | ($0.00B) | $0.01B | ($0.00B) |
| Net Cash from Operations | ($0.18B) | ($0.15B) | ($0.13B) | ($0.13B) | ($0.04B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.24B) | ($0.72B) | ($0.37B) | ($0.38B) | ($0.53B) |
| Sales of Investments | $0.42B | $0.58B | $0.41B | $0.35B | $0.19B |
| Net Cash from Investing | $0.18B | ($0.14B) | $0.04B | $0.25B | ($0.33B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Net Cash from Financing | $0.00B | $0.27B | $0.04B | ($0.03B) | $0.27B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.18B) | ($0.15B) | ($0.13B) | ($0.13B) | ($0.04B) |
| FCF Margin %(computed) | — | — | — | — | -232.39% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Cullinan Therapeutics, Inc. data
About Cullinan Therapeutics, Inc. (CGEM) Cash Flow Statement
Cullinan Therapeutics, Inc. generated operating cash flow of ($0.18B) and free cash flow of ($0.18B) for 2025 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
CGEM · 4 questionsCullinan Therapeutics, Inc. generated free cash flow of ($0.18B) for 2025, down 21.0% year-over-year.
CGEM free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10